HomeQuestion

For cisplatin-ineligible pT4N0M0 renal pelvis UTUC without prior neoadjuvant therapy, do you prefer adjuvant carboplatin/gemcitabine (POUT) or immunotherapy (CheckMate 274)?

1

Join the Discussion

Discuss the cases and questions guidelines don't cover.

Related Questions

Are you planning to start running IHC HER2 testing on all tumor types, even those where HER2 overexpression is less typical, in light of tumor agnostic approval of trastuzumab deruxtecan?

How would you treat a young man with a history of stage IA testicular pure seminoma s/p radical orchiectomy who has a solitary left inguinal lymph node recurrence and normal tumor markers?

When selecting mCRPC patients for Pluvicto, which baseline variables do you find most useful or predictive of potential hematologic toxicity?

Will you extrapolate EORTC 1333/PEACE-3 (enzalutamide + Rad223) to any other ARPIs for mCRPC?

What are your top takeaways from ASCO GU 2026?

Evidence Meets Expertise

For Physicians

Mednet AI
Community

Company

About
Careers
Publications
Blog

Support

FAQs
Code of Conduct
AI Community Guidelines
Contact Us
Programs

Legal

Privacy Policy
Terms of Service

© 2026 Mednet Inc. All rights reserved.